MX2012002610A - Suministro de sdf-1 para el tratamiento de tejido isquemico. - Google Patents
Suministro de sdf-1 para el tratamiento de tejido isquemico.Info
- Publication number
- MX2012002610A MX2012002610A MX2012002610A MX2012002610A MX2012002610A MX 2012002610 A MX2012002610 A MX 2012002610A MX 2012002610 A MX2012002610 A MX 2012002610A MX 2012002610 A MX2012002610 A MX 2012002610A MX 2012002610 A MX2012002610 A MX 2012002610A
- Authority
- MX
- Mexico
- Prior art keywords
- sdf
- left ventricular
- delivery
- ischemic tissue
- treating ischemic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Un método para el tratamiento de una cardiomiopatía en un sujeto que incluye administrar directamente o expresar localmente en una región debilitada, isquémica, y/o de periinfarto del tejido miocárdico del sujeto una cantidad de SDF-1 efectiva para causar mejoramiento funcional en al menos uno de los siguientes parámetros: volumen ventricular izquierdo, área ventricular izquierda, dimensión ventricular izquierda, función cardiaca, prueba de caminata de 6 minutos, o clasificación funcional de la Asociación del Corazón de New York (NYHA).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23777509P | 2009-08-28 | 2009-08-28 | |
US33421610P | 2010-05-13 | 2010-05-13 | |
PCT/US2010/047175 WO2011026041A2 (en) | 2009-08-28 | 2010-08-30 | Sdf-1 delivery for treating ischemic tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012002610A true MX2012002610A (es) | 2012-08-23 |
MX357779B MX357779B (es) | 2018-07-24 |
Family
ID=43628693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012002610A MX357779B (es) | 2009-08-28 | 2010-08-30 | Suministro de sdf-1 para el tratamiento de tejido isquemico. |
Country Status (9)
Country | Link |
---|---|
US (5) | US20120283315A1 (es) |
EP (1) | EP2473196B1 (es) |
JP (1) | JP5856059B2 (es) |
CN (1) | CN102740894B (es) |
AU (1) | AU2010286511B2 (es) |
BR (1) | BR112012004395B8 (es) |
CA (1) | CA2772610C (es) |
MX (1) | MX357779B (es) |
WO (1) | WO2011026041A2 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050271639A1 (en) * | 2002-08-22 | 2005-12-08 | Penn Marc S | Genetically engineered cells for therapeutic applications |
ES2520044T3 (es) | 2007-03-30 | 2014-11-11 | The Cleveland Clinic Foundation | SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos |
WO2009079451A2 (en) | 2007-12-14 | 2009-06-25 | The Cleveland Clinic Foundation | Compositions and methods of promoting wound healing |
JP5856059B2 (ja) | 2009-08-28 | 2016-02-09 | ザ クリーブランド クリニック ファウンデーション | 虚血組織を治療するためのsdf−1送達 |
US9308277B2 (en) | 2010-02-25 | 2016-04-12 | Mesoblast International Sàrl | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
CA2814713A1 (en) * | 2010-10-14 | 2012-04-19 | University Of Central Florida Research Foundation, Inc. | Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium |
US20130136729A1 (en) * | 2011-11-11 | 2013-05-30 | University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group | Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors |
CN105263507A (zh) * | 2013-03-15 | 2016-01-20 | 尤文塔斯医疗公司 | 使用sdf-1减轻瘢痕形成 |
JP6461085B2 (ja) * | 2013-03-15 | 2019-01-30 | ザ クリーブランド クリニック ファウンデーション | 虚血性組織を治療するためのsdf−1送達 |
CA2904540A1 (en) * | 2013-03-15 | 2014-09-18 | The Cleveland Clinic Foundation | Retrograde delivery of sdf-1 for treatment of myocardial infarction |
US20160278810A1 (en) | 2013-05-31 | 2016-09-29 | Mark Edmund Richey | Vaginal surgical apparatus |
US10166044B1 (en) | 2013-05-31 | 2019-01-01 | Freshwater Bay Industries, Llc | Apparatus for repositioning the vagina, cervix, uterus and pelvic floor and method to secure same |
WO2015168145A1 (en) * | 2014-04-28 | 2015-11-05 | Penn Marc S | Sdf-1 delivery for treating advanced ischemic cardiomyopathy |
US10420818B2 (en) | 2014-05-08 | 2019-09-24 | Wake Forest University Health Sciences | Methods of treating incontinence and other sphincter deficiency disorders |
CA2971520C (en) | 2014-12-23 | 2024-04-09 | Ilya Pharma Ab | Methods for wound healing |
MX2018005886A (es) | 2015-11-11 | 2018-08-15 | Intrexon Corp | Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias. |
US11229682B2 (en) | 2017-03-30 | 2022-01-25 | Wake Forest University Health Sciences | Methods of treatment for kidney disease |
WO2018213125A1 (en) | 2017-05-13 | 2018-11-22 | The Johns Hopkins University | Stromal derived factor 1 and it's use in the prevention and treatment of erectile dysfunction |
US11654181B2 (en) | 2017-08-11 | 2023-05-23 | Wake Forest University Health Sciences | Use of CXCL12 for therapy after prostate surgery |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
WO1992008796A1 (en) | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
US5197985A (en) | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US20020031803A1 (en) * | 1997-06-20 | 2002-03-14 | Cooper Mark J. | Expression system for production of therapeutic proteins |
US5602301A (en) | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
CN100569297C (zh) | 1995-02-28 | 2009-12-16 | 加利福尼亚大学董事会 | 基因转移介导的血管形成疗法 |
US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
US5980887A (en) | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
JP2001509168A (ja) * | 1997-01-29 | 2001-07-10 | コーネル リサーチ ファウンデーション、インコーポレイティッド | 血管新生を誘導するためのアデノウイルスベクターの多部位送達 |
CA2289665C (en) | 1997-06-13 | 2005-08-09 | Genentech, Inc. | Protein recovery by chromatography followed by filtration upon a charged layer |
MXPA00003885A (es) | 1997-10-22 | 2004-04-23 | Inst Genetics Llc | Quimiocinas con modificiaciones de la terminacion amino. |
US20030129750A1 (en) * | 1998-02-05 | 2003-07-10 | Yitzhack Schwartz | Homing of donor cells to a target zone in tissue using active therapeutics or substances |
EP1053326A2 (en) | 1998-02-06 | 2000-11-22 | Collateral Therapeutics | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf |
US6676937B1 (en) | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
AU766238B2 (en) | 1998-03-09 | 2003-10-09 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for modulating vascularization |
NZ507161A (en) | 1998-03-30 | 2003-12-19 | Northwest Biotherapeutics Inc | Theraupeutic and diagonistic applications based on the role of the CXCR-4 gene in tumorigenesis |
US20020107195A1 (en) | 1998-07-21 | 2002-08-08 | Smithkline Beecham Corporation | Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha |
IL125532A0 (en) | 1998-07-27 | 1999-03-12 | Yeda Res & Dev | Hematopoietic cell composition for use in transplantation |
AU5241099A (en) | 1998-07-31 | 2000-02-21 | Trustees Of Columbia University In The City Of New York, The | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis |
WO2000015285A1 (en) * | 1998-09-14 | 2000-03-23 | Mirus Corporation | A process for delivering nucleic acids to cardiac tissue |
DE19844479C1 (de) | 1998-09-28 | 2000-04-13 | Siemens Ag | Integrierter Speicher mit einem differentiellen Leseverstärker |
US7399751B2 (en) | 1999-11-04 | 2008-07-15 | Sertoli Technologies, Inc. | Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells |
EP1013770A1 (en) * | 1998-12-23 | 2000-06-28 | Université Louis Pasteur de Strasbourg | Non-viral transfection vector |
DE19900743A1 (de) * | 1999-01-12 | 2000-07-13 | Aventis Pharma Gmbh | Neue komplexbildende Proteine |
WO2000041732A1 (en) | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
US20050153451A1 (en) * | 1999-02-26 | 2005-07-14 | Wolff Jon A. | Intravascular delivery of non-viral nucleic acid |
EP1154780A2 (en) | 1999-02-26 | 2001-11-21 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Bone marrow transplantation for hepatic regeneration and repair |
EP1041148A1 (en) | 1999-04-02 | 2000-10-04 | Mogen International N.V. | Pathogen inducible promoter |
JP2003502282A (ja) | 1999-04-08 | 2003-01-21 | ザ ゼネラル ホスピタル コーポレーション | ヒト転移性細胞の作用因子源から離れた意図された移動 |
US7125856B1 (en) | 1999-04-15 | 2006-10-24 | St. Elizabeth's Medical Center Of Boston, Inc. | Angiogenic growth factors for treatment of peripheral neuropathy |
US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
AU4801501A (en) * | 2000-05-26 | 2001-11-29 | Transgene S.A. | Complex for transferring an anionic substance of interest into a cell |
WO2001094420A1 (en) | 2000-06-05 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
AU2001284695A1 (en) * | 2000-07-31 | 2002-02-13 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
KR20020059609A (ko) * | 2000-08-04 | 2002-07-13 | 벤슨 로버트 에이치. | 혈관 내피 성장 인자 2 |
US20040009940A1 (en) * | 2000-10-20 | 2004-01-15 | Coleman Michael E. | Gene delivery formulations and methods for treatment of ischemic conditions |
US7402567B2 (en) | 2000-10-27 | 2008-07-22 | The Regents Of The University Of California | Treatment of disease by inducing cell apoptosis |
AU2002235168A1 (en) | 2000-11-05 | 2002-05-15 | University Of Florida | Targeting pluripotent stem cells to tissues |
ES2234928T3 (es) | 2000-11-14 | 2005-07-01 | Universite Libre De Bruxelles | Generacion y uso de celulas dendriticas. |
WO2002043758A2 (en) | 2000-12-01 | 2002-06-06 | Schering Corporation | Uses of mammalian genes and related reagents |
AR027161A1 (es) * | 2001-05-15 | 2003-03-19 | Bio Sidus S A | Metodo para inducir la proliferacion neovascular y regeneracion tisular |
US7399740B2 (en) | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
WO2003014336A1 (fr) | 2001-08-07 | 2003-02-20 | Kirin Beer Kabushiki Kaisha | Procede de preparation de cellules souches hematopoietiques multipotentes |
JP4906231B2 (ja) | 2001-09-14 | 2012-03-28 | ステム セル セラピューティクス インコーポレイテッド | プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途 |
US7402724B2 (en) | 2002-01-04 | 2008-07-22 | Mayo Foundation For Medical Education And Research | Longevity and PAPP-A |
WO2003059375A1 (fr) | 2002-01-17 | 2003-07-24 | Cardio Incorporated | Therapie complexe pour la regeneration des tissus |
FR2843697B1 (fr) * | 2002-08-26 | 2005-12-09 | Sod Conseils Rech Applic | L'heterocarpine, une proteine d'origine vegetale aux proprietes anticancereuses |
US7396537B1 (en) | 2002-02-28 | 2008-07-08 | The Trustees Of The University Of Pennsylvania | Cell delivery patch for myocardial tissue engineering |
WO2003077864A2 (en) | 2002-03-15 | 2003-09-25 | Department Of Veterans Affairs, Rehabilitation R & D Service | Methods and compositions for directing cells to target organs |
US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
US20050271639A1 (en) * | 2002-08-22 | 2005-12-08 | Penn Marc S | Genetically engineered cells for therapeutic applications |
US20040161412A1 (en) * | 2002-08-22 | 2004-08-19 | The Cleveland Clinic Foundation | Cell-based VEGF delivery |
US20040037811A1 (en) | 2002-08-22 | 2004-02-26 | The Cleveland Clinic Foundation | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy |
JP2004099471A (ja) | 2002-09-05 | 2004-04-02 | Cardio Corp | 心筋梗塞および心不全の治療薬 |
US7393628B2 (en) | 2002-10-08 | 2008-07-01 | American National Red Cross | Method for enriching adherent monocyte populations |
US20040258669A1 (en) | 2002-11-05 | 2004-12-23 | Dzau Victor J. | Mesenchymal stem cells and methods of use thereof |
JP4672370B2 (ja) | 2002-12-05 | 2011-04-20 | ケース ウエスタン リザーブ ユニバーシティ | 虚血の細胞ベースの治療 |
WO2004074494A1 (ja) * | 2003-02-19 | 2004-09-02 | Dnavec Research Inc. | 虚血疾患の治療方法 |
AU2003902037A0 (en) | 2003-04-24 | 2003-05-15 | Mclachlan, Craig | Method for tissue growth |
US20050104072A1 (en) | 2003-08-14 | 2005-05-19 | Slater David B.Jr. | Localized annealing of metal-silicon carbide ohmic contacts and devices so formed |
US7396680B2 (en) | 2003-10-31 | 2008-07-08 | Cornell Research Foundation, Inc. | Stem cell-specific promoters and their use |
IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
WO2005062881A2 (en) * | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
EP1771196B1 (en) | 2004-06-21 | 2012-03-28 | The Cleveland Clinic Foundation | Ccr ligands for stem cell homing |
CA2584553A1 (en) | 2004-09-17 | 2006-03-23 | Cellgentech, Inc. | External agent for treatment of skin ulcer |
US20070237740A1 (en) * | 2004-09-27 | 2007-10-11 | Vical, Inc. | Formulations and Methods for Treatment of Inflammatory Diseases |
US20060105950A1 (en) | 2004-10-25 | 2006-05-18 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Morphogen compositions and use thereof to treat wounds |
WO2006083394A2 (en) | 2004-12-21 | 2006-08-10 | Ethicon, Inc. | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
US7951632B1 (en) | 2005-01-26 | 2011-05-31 | University Of Central Florida | Optical device and method of making |
GB2424312B (en) | 2005-03-14 | 2010-03-03 | Denso Corp | Method of forming an ohmic contact in wide band semiconductor |
JP2009509339A (ja) | 2005-09-16 | 2009-03-05 | クリー インコーポレイテッド | 炭化ケイ素パワーデバイスを有する半導体ウェハを処理する方法 |
JP5386177B2 (ja) | 2006-01-10 | 2014-01-15 | クリー インコーポレイテッド | 炭化珪素ディンプル基板 |
US20070173471A1 (en) | 2006-01-24 | 2007-07-26 | Losordo Douglas W | Morphogen compositions and methods of use thereof to treat heart disorders |
US7405195B2 (en) | 2006-03-27 | 2008-07-29 | Natural Beauty Bio-Technology Limited | Cosmetic compositions |
ES2520044T3 (es) | 2007-03-30 | 2014-11-11 | The Cleveland Clinic Foundation | SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos |
WO2009079451A2 (en) | 2007-12-14 | 2009-06-25 | The Cleveland Clinic Foundation | Compositions and methods of promoting wound healing |
JP5856059B2 (ja) | 2009-08-28 | 2016-02-09 | ザ クリーブランド クリニック ファウンデーション | 虚血組織を治療するためのsdf−1送達 |
WO2012037083A2 (en) | 2010-09-15 | 2012-03-22 | The Cleveland Clinic Foundation | Compositions and method for promoting musculoskeletal repair |
US20120068161A1 (en) | 2010-09-16 | 2012-03-22 | Lee Keon-Jae | Method for forming graphene using laser beam, graphene semiconductor manufactured by the same, and graphene transistor having graphene semiconductor |
JP5569376B2 (ja) | 2010-12-07 | 2014-08-13 | 住友電気工業株式会社 | 半導体装置の製造方法 |
-
2010
- 2010-08-30 JP JP2012527071A patent/JP5856059B2/ja active Active
- 2010-08-30 CN CN201080043895.7A patent/CN102740894B/zh active Active
- 2010-08-30 WO PCT/US2010/047175 patent/WO2011026041A2/en active Application Filing
- 2010-08-30 EP EP10812718.4A patent/EP2473196B1/en not_active Not-in-force
- 2010-08-30 AU AU2010286511A patent/AU2010286511B2/en not_active Ceased
- 2010-08-30 BR BR112012004395A patent/BR112012004395B8/pt not_active IP Right Cessation
- 2010-08-30 US US13/393,141 patent/US20120283315A1/en not_active Abandoned
- 2010-08-30 CA CA2772610A patent/CA2772610C/en not_active Expired - Fee Related
- 2010-08-30 MX MX2012002610A patent/MX357779B/es active IP Right Grant
-
2012
- 2012-07-24 US US13/556,639 patent/US8513007B2/en active Active
- 2012-07-24 US US13/556,595 patent/US8513213B2/en active Active
-
2013
- 2013-06-07 US US13/912,435 patent/US8883756B2/en active Active
- 2013-12-09 US US14/100,050 patent/US9844581B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN102740894B (zh) | 2015-07-15 |
WO2011026041A9 (en) | 2011-07-21 |
EP2473196B1 (en) | 2017-05-31 |
WO2011026041A2 (en) | 2011-03-03 |
US20120283315A1 (en) | 2012-11-08 |
JP5856059B2 (ja) | 2016-02-09 |
US8513213B2 (en) | 2013-08-20 |
CA2772610A1 (en) | 2011-03-03 |
US8883756B2 (en) | 2014-11-11 |
AU2010286511B2 (en) | 2016-05-26 |
CA2772610C (en) | 2018-01-23 |
BR112012004395B1 (pt) | 2021-01-12 |
US9844581B2 (en) | 2017-12-19 |
EP2473196A4 (en) | 2015-01-07 |
US20120289585A1 (en) | 2012-11-15 |
AU2010286511A1 (en) | 2012-04-12 |
CN102740894A (zh) | 2012-10-17 |
US8513007B2 (en) | 2013-08-20 |
US20120289586A1 (en) | 2012-11-15 |
BR112012004395A2 (pt) | 2016-11-16 |
US20140135383A1 (en) | 2014-05-15 |
MX357779B (es) | 2018-07-24 |
US20130303597A1 (en) | 2013-11-14 |
JP2013503202A (ja) | 2013-01-31 |
EP2473196A2 (en) | 2012-07-11 |
BR112012004395B8 (pt) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012002610A (es) | Suministro de sdf-1 para el tratamiento de tejido isquemico. | |
MY159803A (en) | Treating dyspnea associated with accurate heart failure with relaxin | |
CA2837341C (en) | Method of determining vasoreactivity using inhaled nitric oxide | |
IN2012DN06309A (es) | ||
TN2014000059A1 (en) | Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases | |
WO2009154758A3 (en) | Cardiac rhythm management system with hemodynamic tolerability analyzer | |
EA201591737A1 (ru) | Доставка sdf-1 для лечения ишемизированной ткани | |
CL2015003145A1 (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias | |
WO2011103474A3 (en) | Methods and systems for treating cardiac arrhythmias | |
WO2013188755A3 (en) | Compositions and methods for non-invasive detection and treatment of hypoxic cells in vivo | |
RU2010139486A (ru) | Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин | |
AU2013201629B2 (en) | Treating dyspnea associated with acute heart failure with relaxin | |
UA46421U (ru) | Способ прогнозирования рецидивов фибрилляций предсердий | |
Erdoğan et al. | Long-term safety and efficacy of right ventricular outflow tract compared with apical pacing | |
UA40165U (ru) | Способ оценки уровня кортизола у больных с ишемической болезнью сердца | |
Reynolds | Cardiac resynchronization for heart failure: Its time has come | |
UA71709U (ru) | Способ оценки эффективности лечения симвастатином больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу | |
UA78612U (ru) | Способ оценки эффективности лечения лозартаном больных ишемической болезнью сердца с стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу | |
UA100785U (uk) | Спосіб оцінки ефективності лікування азилсартаном хворих на ішемічну хворобу серця зі стенокардією та артеріальною гіпертензією з порушенням діастолічної функції лівого шлуночка по "гіпертрофічному" типу | |
UA71706U (ru) | Способ оценки эффективности лечения изосорбида мононитратом больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу | |
UA78763U (ru) | Способ лечения синусовой тахикардии у больных острым q-инфарктом миокарда, осложненным аневризмой левого желудочка и острой сердечной недостаточностью | |
UA107786C2 (ru) | Способ оценки эффективности лечения s-амплодипина больных ишемической болезнью сердца с стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическом" типа | |
TN2010000504A1 (en) | Treating dyspnea associated with acute heart failure with relaxin | |
Ferrer et al. | REDUCTION IN LV SIZE AFTER LVAD IMPLANTATION IS ASSOCIATED WITH REDUCTION IN QRS VOLTAGE AND DURATION | |
Kojima | Cibenzoline/ciclosporin interaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |